Generic Name: olaparib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Lynparza is a PARP inhibitor approved for first-line maintenance treatment of ovarian cancer in women with harmful BRCA mutations, maintenance treatment of recurrent ovarian cancer that is responding to chemotherapy, previously treated advanced ovarian cancer in patients with BRCA mutations, and previously treated HER2-negative metastatic breast cancer in people with BRCA mutations.
Lynparza blocks poly ADP-ribose polymerase (PARP) proteins, which play a role in DNA damage repair. Inhibiting PARP leads to more DNA breaks in cancer cells, which halts cell division. People with harmful BRCA mutations do not make proteins that repair this kind of DNA damage, so BRCA-related cancers are especially susceptible to these drugs.
The SOLO-2 trial showed that Lynparza improved progression-free survival (PFS) in women with BRCA-related ovarian, fallopian tube or primary peritoneal cancer who experienced recurrence during platinum-based chemotherapy. SOLO-3 showed that Lynparza led to better response rates than chemotherapy for previously treated BRCA-mutated advanced ovarian cancer. SOLO-1 showed that Lynparza as frontline maintenance therapy reduced the risk of disease progression or death by 70 percent in women with newly diagnosed BRCA-mutated advanced ovarian cancer. The OlympiAD study showed that Lynparza extended PFS in women with BRCA-mutated HER2-negative metastatic breast cancer. Lynparza was first approved in 2014.
Lynparza is taken as a tablet or capsule twice daily with or without food.
Common side effects include nausea and vomiting, fatigue, diarrhea, muscle and joint pain, headache, unusual taste sensations, decreased appetite, mouth sores and constipation. Lynparza can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects include lung inflammation and increased risk of leukemia or myelodysplastic syndrome. Lynparza should not be used during pregnancy
For More Info: https://www.lynparza.com/
Patient Assistance Program Info: https://www.lynparza.com/ovarian-cancer/patient-resources/my-lynparza-support-program.html
Last Reviewed: December 19, 2018